Cover Image

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p

Saved in:
Bibliographic Details
Main Authors: Lokhorst, Henk M. (Author) , Schmidt-Wolf, Ingo (Author) , Sonneveld, Pieter (Author) , Holt, Bronno van der (Author) , Martin, Hans (Author) , Barge, Rene (Author) , Bertsch, Uta (Author) , Schlenzka, Jana (Author) , Bos, Gerard M. J. (Author) , Croockewit, Sandra (Author) , Zweegman, Sonja (Author) , Breitkreutz, Iris (Author) , Joosten, Peter (Author) , Scheid, Christof (Author) , Marwijk-Kooy, Marinus van (Author) , Salwender, Hans-Juergen (Author) , Oers, Marinus H. J. van (Author) , Schaafsma, Ron (Author) , Naumann, Ralph (Author) , Sinnige, Harm (Author) , Blau, Igor (Author) , Delforge, Michel (Author) , Weerdt, Okke de (Author) , Wijermans, Pierre (Author) , Wittebol, Shulamiet (Author) , Duersen, Ulrich (Author) , Vellenga, Edo (Author) , Goldschmidt, Hartmut (Author)
Format: Article (Journal)
Language:English
Published: [January, 2008]
In: Haematologica, the hematology journal
Year: 2008, Volume: 93, Issue: 1, Pages: 124-127
ISSN:1592-8721
DOI:10.3324/haematol.11644
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.11644
Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/4696
Get full text
Author Notes:Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M. J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreutz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H. J. van Oers, Ron Schaafsma, Ralph Naumann, Harm Sinnige, Igor Blau, Michel Delforge, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, and Hartmut Goldschmidt for Dutch-Belgian HOVON and German GMMG
Description
Summary:In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p
Item Description:Gesehen am 21.01.2022
Physical Description:Online Resource
ISSN:1592-8721
DOI:10.3324/haematol.11644

Similar Items